Aims/hypothesis Combinations of autoantibody characteristics, including antibody number, titre, subclass and epitope have been shown to stratify type 1 diabetes risk in islet autoantibody-positive relatives. The aim of this study was to determine whether autoantibody characteristics change over time, the nature of such changes, and their implications for the development of diabetes. Methods Five-hundred and thirteen follow-up samples from 141 islet autoantibody-positive first-degree relatives were tested for islet autoantibody titre, IgG subclass, and GAD and IA-2 antibody epitope. All samples were categorised according to four risk stratification models. Relatives had a median follow-up of 6.8 years and 48 developed diabetes during follow-up. Survival analysis was used to determine the probability of change in risk category and of progression to diabetes. Results For each stratification model, the majority of relatives (71-81%) remained in the same risk category throughout follow-up. In the remainder, changes occurred both from lower to higher and from higher to lower risk categories. For all four models, relatives aged <15 years were more likely to change risk category than those aged >15 years (0.001<p<0.03). Relatives whose autoantibody status changed from low-to high-risk categories had a higher risk of diabetes than relatives who remained in low-risk categories, and inclusion of autoantibody status during follow-up improved diabetes risk stratification in Cox proportional hazards models (p<0.001). Conclusions/interpretation Changes in islet autoantibodies are relevant to pathogenesis, and are likely to signal alterations in the disease process. Detection of changes through follow-up measurement will improve diabetes risk stratification, particularly in young individuals.
glutamate decarboxylase (GADA), and the protein tyrosine phosphatase-like antigen IA-2 (IA-2A) are established risk markers for type 1 diabetes [2, 3] , and risk is related to the titre of islet cell antibodies [4, 5] and to the number of autoantibodies [6] [7] [8] [9] [10] . In addition, we recently reported that risk can be stratified using algorithms of autoantibody characteristics, including IAA and IA-2A titre, IAA and IA-2A IgG subclass, and antibody binding to the IA-2β autoantigen [11] . Applying models based on these algorithms to a single sample, diabetes risk in autoantibodypositive relatives could be further stratified from less than 10% to almost 100% within 5 years of screening. To use these stratification models most efficiently, we need to know whether an individual's assigned risk category changes over time, and the implications of any such changes for the development of diabetes. We therefore examined risk assignment based on these models in serial samples from 141 antibody-positive first-degree relatives, and assessed the effect of changes on diabetes risk.
Subjects and methods

Subjects
This study was performed on 141 of the 180 autoantibodypositive relatives from the Bart's-Oxford (BOX; n=67) and the Munich family studies (n=74) [12, 13] previously used to define the risk stratification models [11] . Relatives for this study were selected on the basis of the availability of followup samples to allow testing of all antibody characteristics (titre, IgG subclasses of IAA and IA-2A, antibodies to IA-2β ). The study cohort contained 49 offspring (30 sons, 19 daughters), 52 siblings (24 brothers, 28 sisters), and 40 parents (17 fathers, 23 mothers) of the diabetic proband. The first available autoantibody-positive serum sample and subsequent follow-up samples from these relatives were used for antibody characterisation (total 513 samples; median number of samples per relative 3, interquartile range (IQR) 2-4, range 2-11; median time between samples 1.8 years, IQR 1.2-2.4 years). The median age of relatives at time of first sample was 15.0 years (IQR 8.3-32.5 years). Relatives were prospectively monitored for the development of diabetes over a median follow-up period of 6.8 years (IQR 4.6-12.3 years) for a total of 1145 subject-years. The median follow-up was 5.9 years (IQR 3.7-8.2) for relatives aged <15 years, and 9.7 years (IQR 5.8-13.8) for relatives aged >15 years (p< 0.001). Of the 141 autoantibody-positive relatives, 48 developed diabetes during follow-up (median time to diabetes 4.4 years, IQR 2.2-6.3 years). Diabetes was diagnosed using World Health Organization/American Diabetes Association criteria [14] . The respective local ethical committees approved the BOX and Munich family studies. All relatives in this study gave informed consent, and the study was carried out in accordance with the Declaration of Helsinki as revised in 2000 http://www.wma.net/e/policy/b3.htm, last accessed in August 2006).
Islet autoantibody measurements
IAA, GADA and IA-2A were measured in all 513 samples by protein A/G radiobinding assays, as previously described [9, 15] [11] . The thresholds for positivity in each assay corresponded to the 99th percentile for antibody titre in control subjects. These assays had sensitivities and specificities of 70% and 99% (IAA), 86% and 93% (GADA), and 72% and 100% (IA-2A), respectively, in the Third Diabetes Autoantibody Standardization Program workshop.
IA-2βA were determined in IA-2A-positive samples by protein A/G radiobinding assays using a [
35 S]methioninelabelled, in vitro-translated recombinant human intracellular portion of IA-2β (amino acids 662-1033) [11, 16] . IgG subclasses of IAA and IA-2A were determined by radiobinding assays as previously described [11, 17] .
Data analysis
Diabetes risk stratification models All 513 samples were classified according to categories of four diabetes risk stratification models, which had been previously developed on the basis of autoantibody status in the first available islet autoantibody-positive samples from 180 relatives [11] . Models are described in Fig. 1 .
Statistical analysis
The Mann-Whitney U-test or KruskalWallis H-test was used to compare differences in age between groups. The Wilcoxon test was used to compare directional changes in model risk categories between the first and last sample. Life table analysis was used to determine the probability of change in model category and the diabetes risk. For analysis of the probability of change in model category, the time to event was defined by the first autoantibody-positive sample, and the end of follow-up was defined by the sample in which first change in category occurred or the date of the last sample tested in relatives who did not change category. The probability of change in category was compared between relatives <15 and ≥15 years of age (50th percentile for age) using the log rank test. For analysis of diabetes risk, the time to event was defined from the first change in model category or from the first autoantibody-positive sample in relatives who did not change category, and the end of follow-up was defined as date of diagnosis, date of entry into an intervention trial or date of last contact. Survival between groups was compared using the log rank test. For all analyses, a two-tailed p value of 0.05 was considered significant; values were not corrected for number of comparisons using the four models. Cox proportional hazards models were used to analyse the influence of change over time on the performance of each model. The outcome was diagnosis of diabetes, and assigned risk categories were entered as time-dependent covariates with 1-year intervals. The category assigned to each time interval was the autoantibody status in the last sample prior to that time point. Improvement in risk stratification using models based on first measurement and follow-up samples was assessed by change in log likelihood ratio. All statistical analyses were performed using the Statistical Package for Social Science, version 13.0 (SPSS, Chicago, IL, USA).
Results
Classification according to risk categories of each of the four stratification models was done for 513 follow-up samples of 141 relatives. Example timelines are shown for Models 1 and 4 ( Fig. 2 ). For each model, the majority of relatives remained in the same risk category throughout follow-up (71% of relatives in Model 1, 75% in Model 2, 72% in Model 3, 81% in Model 4). In relatives whose risk category changed, individual changes were usually unidirectional rather than fluctuating (Table 1) . A preferential direction of change was observed only for Model 4 ( Fig. 2b) , in which shifts from lower to higher risk categories were more frequent than shifts from higher to lower risk categories (p=0.03; not significant for Models 1, 2 or 3). Three relatives (2.1%) lost all antibody reactivity on follow-up (age at first sample 16, 20 and 47 years). None of these relatives re-developed islet autoantibodies and none developed diabetes.
Relatives who changed risk category were younger at time of first autoantibody-positive sample than relatives whose category remained stable ( Fig. 3a) . The risk of diabetes in relatives who changed to high-risk categories was similar to the risk in those who remained stable in high-risk categories throughout followup. In all models, few relatives changed from high-risk to low-risk categories, and only in Model 2 were relatives in this group at significantly lower risk than those who remained stable in high-risk categories (p=0.02) (Fig. 3b) . In Model 3, however, diabetes risk remained high in relatives who decreased from high-to low-risk categories. Table 2 shows Cox proportional hazards models based on the antibody characteristics in the first sample alone (Cox Model A) and on the characteristics in follow-up samples (Cox Model B). Consideration of changes in categories over time significantly improved diabetes risk stratification (p= 0.02, Model 1; p<0.001, Models 2, 3, and 4; Table 2 ). Seventy-four relatives were in high-risk categories at screening or during follow-up using Model 1, 61 using Model 2, 40 using Model 3, and 39 using Model 4. The 5-year risk for progression to diabetes in these relatives was 33% in Model 1 (95% CI 21. 
Discussion
We have shown that repeated testing of islet autoantibodies over time in autoantibody-positive first-degree relatives identified a subgroup of around 25% in whom there is a Fig. 3 Type 1 diabetes risk stratified in 141 antibody-positive relatives taking into consideration changes in risk category of stratification models on follow-up. Relatives were followed for diabetes development from time of first change in model risk category or first antibody-positive sample in relatives who did not change risk category throughout follow-up. For each model, relatives who remained stable in low-risk categories (thick solid line) are compared with relatives who increased from low-risk to high-risk categories (broken line) (a), and relatives who remained stable in high-risk categories (thin solid line) are compared with relatives who decreased from high-risk to low-risk categories (dotted/dashed line) (b). Lowrisk and high-risk categories of models were considered as described change in antibody status that is indicative of a different diabetes risk. Change in antibody status was usually persistent and occurred more often in children and adolescents than in adults. The findings are relevant to staging of diabetes risk and suggest that monitoring islet autoantibody status and risk categorised on the basis of antibody characteristics is likely to improve our ability to predict diabetes in relatives at risk. The study was performed on autoantibody-positive relatives that have had up to 18 years of follow-up with frequent sampling. The cohort included 48 relatives who developed diabetes, as well as 47 who remained nondiabetic for more than 10 years. In this study we focused on the selected number of antibody characteristics, which we have previously found to be the most significant predictors of diabetes in the same cohort [11] . These characteristics allowed stratification of diabetes risk into three or more discrete model risk categories which, as shown by the data, were relatively robust and stable over time. Although changes in autoantibody titre, IgG subclass and epitope were observed in many relatives (data not shown), these did not usually result in changes in risk category. For example, changes in antibody characteristics of GADA did not affect risk categories in any of our models, and changes in antibody titre of IAA or IA-2A were not always associated with a change in risk category in Model 2 or 3 (i.e. titre change did not cross the 75th percentile for titre of IAA or the 25th percentile for titre of IA-2A). A limitation of the study is the fact that we did not assess the metabolic makers that have been shown to provide added specificity for disease progression in autoantibody-positive relatives [18] [19] [20] . Similarly, we were unable to assess T cell reactivity, which might have provided further insights into the relevance of our findings to disease pathogenesis [21] .
Measures that monitor progression to type 1 diabetes should be sensitive in identifying changes relevant to pathogenesis, and changes in risk category should not be seen in the absence of relevant pathogenic events. Using standard (antibody number) and more sophisticated models of risk stratification based on islet autoantibodies, we report that risk categories were stable over time for the majority of relatives, and that the rate of progression to diabetes was reasonably linear in relatives in whom autoantibody status remained unchanged. Thus, for the majority of autoantibody-positive relatives, the risk assigned at screening provided a relatively accurate assessment throughout follow-up. These findings are in line with the remarkable concordance between the diabetes risk predicted from the screening samples and the actual diabetes progression in the European Nicotinamide Diabetes Intervention Trial (ENDIT) [22] and the Diabetes Prevention Trial-1 (DPT-1) [23, 24] . Follow-up measurement was useful in a minority of autoantibody-positive relatives, and the use of autoantibody status as a time-dependent covariate in the cohort significantly improved diabetes risk assessment in comparison with the use of the screening value alone. Around 20% of the relatives had a persistent change in antibody status. These were generally younger relatives, and few changes in antibody risk category were observed in adulthood. Changes were predominantly unidirectional in any single individual, but occurred in both directions within a given model (increase in risk category in some relatives and decrease in others). It is interesting that changes from low-to very-highrisk categories often occurred abruptly over a short time (Fig. 2b) , suggesting that such changes mark pathogenic events that alter the course of the disease. This is also reflected by the observation that changes in autoantibody status were associated with changes in diabetes risk. In particular, changes to higher risk categories were associated with faster progression to diabetes. The effect of change in autoantibody status to lower risk categories was less consistently associated with change in actual risk. The number of relatives who changed from a high-risk to a lower risk category during follow-up was, however, small (two relatives in Model 4 to ten relatives in Model 1). A few of the relatives whose high-risk category fell actually progressed rapidly to diabetes. This phenomenon was generally seen in association with the loss or decrease of IAA titre during follow-up, and is consistent with previous reports that IAA titre is inversely related to age [25] and a loss of IAA may occur prior to diabetes onset [26] .
The findings from this and previous studies [7, [27] [28] [29] indicate that age is a determinant of risk of type 1 diabetes. Younger islet autoantibody-positive relatives were more likely to be in high-risk categories and were more likely to change from low-risk to high-risk categories than older relatives. The majority of adult autoantibody-positive relatives had low-risk antibody profiles (e.g. single GADA-positive only). These relatives had a steady but slow rate of progression to diabetes. The measurement of additional markers, such as autoantibody affinity or metabolic testing, may better identify progressors in this subgroup [29] [30] [31] .
We have shown that diabetes risk stratification using autoantibodies can be improved by considering criteria other than just antibody number [6, 7, 10] . Previously, algorithms that considered IAA and IA-2A titre, IgG subclass and/or IA-2βA status were able to stratify type 1 diabetes risk at a single time point better than classification on the basis of antibody number alone [11] . Here, we find that these same algorithms improve risk stratification even further when autoantibody characteristics in follow-up samples are also considered. Model 4, based simply on IA-2βA positivity was particularly powerful in identifying relatives at high risk. A total of 39 relatives had IA-2βA at screening or during follow-up. This group had an overall 5-year risk of diabetes of 64%, and included 26 of the 48 relatives who developed diabetes during follow-up. Of the four models described, Model 1, based on antibody number, and Model 4, based on autoantibodies to IA-2 and IA-2β, are likely to be the most practical for general application, and measurement of IA-2βA could be introduced to large-scale screening and recruitment to intervention trials.
In summary, our results support the use of follow-up measurements of islet autoantibodies in autoantibodypositive relatives for improved diabetes risk stratification and increased sensitivity of identification of pre-type 1 diabetes. Determination of antibody characteristics in follow-up samples identified up to 50% more relatives who had a >50% risk of diabetes. Changes were mainly seen in the younger relatives, suggesting that follow-up autoantibody testing could be restricted to children and adolescents.
